AAAAAA
Results:
1-14
|
Results: 14
Authors:
Dezutter, NA
Landman, WJM
Jager, PL
de Groot, TJ
Dupont, PJ
Tooten, PCJ
Zekarias, B
Gruys, E
Verbruggen, AM
Citation: Na. Dezutter et al., Evaluation of Tc-99m-MAMA-chrysamine G as an in vivo probe for amyloidosis, AMYLOID, 8(3), 2001, pp. 202-214
Authors:
Vanbilloen, HP
Busson, R
Verbruggen, AM
Citation: Hp. Vanbilloen et al., Structural requirements for stable binding of technetium-99m to derivatives of triglycine, J LABEL C R, 44(2), 2001, pp. 99-111
Authors:
Dezutter, NA
Sciot, RM
de Groot, TJ
Bormans, GM
Verbruggen, AM
Citation: Na. Dezutter et al., In vitro affinity of Tc-99(m)-labelled N2S2 conjugates of chrysamine G foramyloid deposits of systemic amyloidosis, NUCL MED C, 22(5), 2001, pp. 553-558
Authors:
Vanbilloen, HP
Cleynhens, BJ
Verbruggen, AM
Citation: Hp. Vanbilloen et al., Synthesis and biological evaluation of the four isomers of technetium-99m labeled ethylenecysteamine cysteine (Tc-99m-ECC), the mono-acid derivative of Tc-99m-L,L-ethylenedicysteine, NUCL MED BI, 27(2), 2000, pp. 207-214
Authors:
Vanbilloen, HP
Mortelmans, L
Verbruggen, AM
Citation: Hp. Vanbilloen et al., Reduction of contamination risks during clinical studies with Technegas - Reply, EUR J NUCL, 27(2), 2000, pp. 238-238
Authors:
Du Raan, H
Lotter, MG
Harris, GW
van Aswegen, A
Otto, AC
Nel, MG
Badenhorst, PN
Verbeke, KA
Verbruggen, AM
Citation: H. Du Raan et al., Measurement of plasma volume using Tc-99(m)-labelled DMP-HSA, NUCL MED C, 21(6), 2000, pp. 539-544
Authors:
Hjelstuen, OK
Saetern, AM
Tonnesen, HH
Bremer, PO
Verbruggen, AM
Citation: Ok. Hjelstuen et al., Development of a lyophilized kit formulation for labeling of DNA probes with Tc-99m, INT J PHARM, 190(2), 1999, pp. 197-205
Authors:
Hjelstuen, OK
By, BC
Cleynhens, B
Ormstad, HM
Roald, TE
Tonnesen, HH
Bremer, PO
Verbruggen, AM
Citation: Ok. Hjelstuen et al., Comparative evaluation of Tc-99m-MAG2-oligodeoxynucleotides with phosphodiester or phosphorothioate backbones: Preparation, stability and biodistribution, J LABEL C R, 42(8), 1999, pp. 737-760
Authors:
Dezutter, NA
de Groot, TJ
Vanbilloen, HP
Janssen, GA
Verbruggen, AM
Citation: Na. Dezutter et al., Preparation and biological evaluation of technetium-99m-L,L-propylenedicysteine, J LABEL C R, 42(6), 1999, pp. 553-565
Authors:
Dezutter, NA
de Groot, TJ
Busson, RH
Janssen, GA
Verbruggen, AM
Citation: Na. Dezutter et al., Preparation of Tc-99m-N2S2 conjugates of chrysamine G, potential probes for the beta-amyloid protein of Alzheimer's disease, J LABEL C R, 42(4), 1999, pp. 309-324
Authors:
Hjelstuen, OK
Maelandsmo, GM
Tonnesen, HH
Bremer, PO
Verbruggen, AM
Citation: Ok. Hjelstuen et al., Uptake of Tc-99m- and P-32-labelled oligodeoxynucleotides in an osteosarcoma (OHS) cell line, J LABEL C R, 42(12), 1999, pp. 1215-1227
Authors:
Dezutter, NA
Dom, RJ
de Groot, TJ
Bormans, GM
Verbruggen, AM
Citation: Na. Dezutter et al., Tc-99m-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease, EUR J NUCL, 26(11), 1999, pp. 1392-1399
Authors:
Vanbilloen, HP
Bauwens, J
Mortelmans, L
Verbruggen, AM
Citation: Hp. Vanbilloen et al., Reduction of contamination risks during clinical studies with Technegas, EUR J NUCL, 26(10), 1999, pp. 1349-1352
Authors:
van Aswegen, A
Marais, J
Kemp, G
Nel, MG
van Staden, JA
Otto, AC
Lotter, MG
Verbruggen, AM
Citation: A. Van Aswegen et al., Biodistribution and absorbed radiation dose estimates of Tc-99m-labeled dimercaptopropionyl human serum albumin, J NUCL MED, 40(9), 1999, pp. 1532-1535
Risultati:
1-14
|